ADMA Biologics Receives BioNJ 2020 Innovator Award for ASCENIV?

RAMSEY, N.J. and BOCA RATON, Fla., Feb. 11, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and for the prevention of certain infectious diseases, today announced that it was awarded the BioNJ 2020 Innovator Award in recognition of the development and approval of ASCENIV? (immune globulin intravenous, human ? slra 10% liquid) by the U.S. Food and Drug Administration (FDA) in 2019.

Click to view original post